Recently, several novel gene signatures in LSCs are identified to monitor the function and activity of LSCs after CML patients receive BCR-ABL kinase inhibitors treatment or other novel therapies (Table 1 and Figure 1). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.